PDE4A and aneurysm: We found that the systemic administration of rolipram, the prototypical selective PDE4 inhibitor, to AngII-challenged mice limited the growth of the aortic diameter, as assessed by ultrasonography, while reducing the incidence and severity of aneurysm.